about
Genetic Research and Women's Heart Disease: a PrimerValidity of Cardiovascular Disease Event Ascertainment Using Linkage to UK Hospital RecordsBacterial Community Profile of the Gut Microbiota Differs between Hypercholesterolemic Subjects and ControlsThe Role of Efferocytosis in Atherosclerosis.A path to precision in the ICU.Inflammation - Cause or Consequence of Heart Failure or Both?Utilizing nutritional genomics to tailor diets for the prevention of cardiovascular disease: a guide for upcoming studies and implementations.Toward Precision Healthcare: Context and Mathematical ChallengesTwenty-First Century Diseases: Commonly Rare and Rarely Common?Can learning health systems help organisations deliver personalised care?Tailoring of medical treatment: hemostasis and thrombosis towards precision medicineComputational profiling of the gut-brain axis: microflora dysbiosis insights to neurological disorders.Personalized medicine-a modern approach for the diagnosis and management of hypertension.Personalized Management of Cardiovascular Disorders.Effects of Exercise on Arrhythmia (and Viceversa): Lesson from the Greek Mythology.Biomarker definitions and their applications.Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.Palliative treatment of coronary "atherosclerotic cancer" by drug-eluting or bare-metal stents: From oculo-stenotic reflex period to age of precision medicine.The integration of genomics testing and functional proteomics in the era of personalized medicine.Epigenetics and precision medicine in cardiovascular patients: from basic concepts to the clinical arena.Emerging Role of Precision Medicine in Cardiovascular Disease.Precision Psychiatry Meets Network Medicine: Network Psychiatry.Patient-Specific Cardiovascular Computational Modeling: Diversity of Personalization and Challenges.Glycosylation Profile of Immunoglobulin G Is Cross-Sectionally Associated With Cardiovascular Disease Risk Score and Subclinical Atherosclerosis in Two Independent Cohorts.Network-based approach to prediction and population-based validation of in silico drug repurposing.
P2860
Q28069638-98928D2D-46C7-4D2E-9E8B-A35DD8A81B67Q30491845-41EA0ACA-33A6-421D-9E1E-0C6139598ABBQ33862400-2A967C48-2883-4D4E-9ADA-755D03CCD038Q34680660-34B89FE7-DB02-43A5-B35D-FBF7208ED6D8Q37733894-8EB5CB02-F341-49C9-914E-BBB86585DEF7Q38664204-58F7AB1D-D805-472B-B421-F00B99520F69Q38740539-AB5FE2E0-F4C0-4041-91AF-F8F475011DDDQ38854423-632E72D2-F997-401A-BFC7-6280DB2D6781Q40210458-6348A6FF-92C7-4A92-8967-5818DD863152Q42288102-B7C57B1C-96B5-47E9-B091-BC602A75F7E8Q42361969-A8AFE63D-D1C4-476A-B6CC-5A53D8FBA8EDQ46251992-4420C7A1-439F-4866-9C0E-E1D4E4E21AAEQ47095825-F85490A1-59F7-4ECE-8DB3-C5C5E5C10B30Q47690029-634B34C8-8A37-423D-97A6-D790B76BB6B7Q47724722-A0F6A93D-AB13-466C-A4E4-DEABD4807305Q48500157-F358338E-5A5E-4EC4-972D-DA4CD52A5BB1Q49833189-0C839643-1FBB-40E8-8BB6-5FFA90320EE8Q49887626-51E9476A-4332-4E62-A69C-2B5F3F97FE58Q50078274-6A08A847-B284-4B2D-9215-303B16AE8C64Q50082577-E5FC9730-F6ED-45BB-A616-C881D817788BQ53748314-1C10EC59-95A2-4E5A-BB11-E499BF061109Q54188653-3FA215AD-F946-4053-81D7-A42433AE3A3FQ55113976-7217450C-CCCA-47D7-BF3B-25043FE65D5AQ55420505-37592A16-F534-432A-A4C7-CDFAC90E9871Q55643995-06FC0B18-71DD-4260-97BB-6C8C6FD0AC0E
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Precision medicine in cardiology.
@ast
Precision medicine in cardiology.
@en
type
label
Precision medicine in cardiology.
@ast
Precision medicine in cardiology.
@en
prefLabel
Precision medicine in cardiology.
@ast
Precision medicine in cardiology.
@en
P1476
Precision medicine in cardiology.
@en
P304
P356
10.1038/NRCARDIO.2016.101
P407
P577
2016-06-30T00:00:00Z